Search

Baloxavir Patent for Influenza Prevention Transmission

The EPO published application EP3714889A1 on April 15, 2026, disclosing the Baloxavir patent covering use of the antiviral compound for prevention of influenza virus transmission. The application is co-owned by F. Hoffmann-La Roche AG and Shionogi & Co., Ltd, with designated states covering all major European markets (DE, FR, GB, IT, ES, NL, BE, AT, CH, and 21 others).

Roche Patents Blood Glucose Prediction System for Adverse Range Determination

The European Patent Office published patent application EP3651164A1, filed by Roche Diabetes Care GmbH, F. Hoffmann-La Roche AG, and mySugr GmbH. The patent covers methods and systems for determining the probability of a patient's blood glucose value falling within an adverse range at a specified prediction time. The patent is classified under G16H 50/20, 50/30, and 50/70 for health informatics diagnostics.

Alecensaro Alectinib Risk of Severe Hypertriglyceridemia and Acute Pancreatitis

Health Canada has identified severe hypertriglyceridemia as a newly characterized adverse reaction associated with Alecensaro (alectinib) in lung cancer patients. Clinical trial data showed hypertriglyceridemia events of any grade in 4.3% of patients and severe or life-threatening events in 1.5%, while five medically confirmed post-marketing cases were reported internationally, including three cases of life-threatening pancreatitis with all patients recovering following treatment. Health Canada is requiring triglyceride monitoring at baseline and periodically, temporary withholding of Alecensaro if triglycerides exceed specified thresholds or pancreatitis occurs, and an update to the Canadian Product Monograph.

Roche Oligonucleotides for Paternal UBE3A Expression

The European Patent Office published patent application EP3798307A1 for F. Hoffmann-La Roche AG covering oligonucleotides designed to induce paternal UBE3A expression. The invention relates to nucleic acid therapeutics targeting UBE3A gene expression, with applications in treating genetic disorders. The patent application was filed under IPC classification C12N 15/113 and designates all 39 contracting states across the European Patent Convention.

Oligonucleotides for Inducing Paternal UBE3A Expression - Angelman Syndrome Treatment

USPTO granted patent US12596118B2 to Hoffmann-La Roche Inc. covering oligonucleotides capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele for treatment of Angelman syndrome. The 30 claims target the suppressor of the UBE3A paternal allele via hybridization to SNHG14 long non-coding RNA downstream of SNORD109B.

Methods of Treating Locally Advanced or Metastatic Breast Cancers Using PD-1 Axis Binding Antagonists and Taxanes

The European Patent Office published patent application EP3310815A1, filed by F. Hoffmann-La Roche AG, covering methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists in combination with taxanes. Inventor is Daniel S. Chen. The publication includes IPC classifications covering therapeutic antibodies, antineoplastic compositions, and designated states for national phase entry.

Hoffmann-La Roche Granted Amino-Pyrimidine Amide Patent US12600712B2

USPTO granted Patent US12600712B2 to Hoffmann-La Roche Inc. on April 14, 2026, covering amino-pyrimidine amide compounds with general formula (I) and methods of using such compounds. The patent includes 11 claims and CPC classifications C07D 403/06 and C07D 491/107 in organic chemistry. The filing date was December 7, 2022, with Application No. 18062644.

Tumor-Targeted Bispecific CD28 Antigen Binding Molecules Patent Grant

USPTO granted patent US12600781B2 to Hoffmann-La Roche Inc. covering tumor-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28. The patent includes 51 claims covering the binding molecules, methods of production, pharmaceutical compositions containing these antibodies, and methods of using the same for cancer treatment.

Method for Increasing Recombinant Protein Expression

The USPTO published patent application US20260098271A1 assigned to Hoffmann-La Roche Inc., covering a method for increasing recombinant protein expression through use of a nucleic acid encoding a selection marker, self-cleaving peptide sequence, and proteinaceous protease inhibitor. The invention aims to increase heterologous polypeptide production by reducing protease cleavage. The application was filed on May 20, 2025.

Treatment of Cancer Using Anti-HLA-G/Anti-CD3 Bispecific Antibody and 4-1BB Agonist

The USPTO published patent application US20260092118A1 by Hoffmann-La Roche Inc., covering a method for treating cancer using an anti-HLA-G/anti-CD3 bispecific antibody in combination with a 4-1BB (CD137) agonist. The application (No. 19325175) was filed September 10, 2025, and lists Meher Majety, Carina Hage, and Johannes Sam as inventors. This publication represents an early-stage intellectual property filing for a bispecific antibody-based cancer therapy.

Novel Heterocyclic Compounds for Pharmaceutical Use

Hoffmann-La Roche Inc. published patent application US20260092076A1 for novel heterocyclic compounds with pharmaceutical use. The application covers compounds having general formula I with defined R1, R2, R3, A and W substituents, related compositions, and methods of using the compounds. Filing date was October 7, 2025, under Application No. 19351608.

Novel Heterocyclic Compounds Patent Application

The USPTO published patent application US20260092073A1 by Hoffmann-La Roche Inc. for novel heterocyclic compounds with general formula I, including compositions and methods of use. The application (Filing Date: 2025-10-15) covers compounds where R1, R2, R9, A1, Rx and Ry define specific substituents. Inventors include David BON, Lea Aurelie BOUCHE, Wolfgang GUBA, and others. CPC Classification: C07D 498/04.

Annelated Pyridines as Steroidogenesis Inhibitors

USPTO published patent application US20260092074A1 by Hoffmann-La Roche covering annelated pyridine compounds as steroid synthetase inhibitors for pharmaceutical use. The application, filed September 25, 2023, discloses small-molecule heterocyclic compounds (C07D class) with applications in steroid hormone regulation. Inventors include Qingzhong Hu, Lina Yin, and Haiyan Li.

Methods to Decrease Impurities from Recombinant Protein Manufacturing Processes

The USPTO granted Patent US12595294B2 to Hoffmann-La Roche Inc. on April 7, 2026. The patent covers methods for reducing non-aggregate produce-related impurities (NAPRIs) in buffered solutions of monoclonal antibodies using synthetic depth filters. Inventors are Marc Pompiati and Christoph Feistl, with 15 claims in the granted patent.

USPTO Patent Application for Immunoconjugates

The USPTO has published a new patent application, US20260083855A1, filed by Hoffmann-La Roche Inc. The application relates to immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This filing is part of the standard patent application process.

Fc-IL2 variant cancer therapy combination patents

USPTO published patent application US20260091062A1 by Hoffmann-La Roche Inc. covering recombinant Fc domain-IL-2 variant polypeptides combined with membrane-anchored antigen binding polypeptides for cancer treatment. The application (No. 19272092) was filed July 17, 2025, and published April 2, 2026.

All-in-one Agonistic Antibodies Patent Application

The USPTO has published a patent application (US20260085113A1) filed by Hoffmann-La Roche Inc. on October 2, 2025. The application describes antigen binding molecules comprising biparatopic target-binding domains and cytokine receptor-binding domains designed to selectively activate cytokine receptors.